HRS-9190 for Injection
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Skeletal Muscle Relaxation
Conditions
Skeletal Muscle Relaxation
Trial Timeline
Apr 23, 2025 → Aug 13, 2025
NCT ID
NCT06932315About HRS-9190 for Injection
HRS-9190 for Injection is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Skeletal Muscle Relaxation. The current trial status is completed. This product is registered under clinical trial identifier NCT06932315. Target conditions include Skeletal Muscle Relaxation.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06932315 | Phase 1 | Completed |
Competing Products
9 competing products in Skeletal Muscle Relaxation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochloride | Eisai | Phase 3 | 77 |
| No intervention | Johnson & Johnson | Pre-clinical | 23 |
| HRS-9190 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| ACE-083 | Merck | Phase 1 | 33 |
| BYM338 + Placebo | Novartis | Phase 2 | 52 |
| Lumiracoxib | Novartis | Approved | 85 |
| Nerve Growth Factor | Lundbeck | Pre-clinical | 20 |
| Botulinum toxin type A | Ipsen | Phase 3 | 74 |
| Burosumab | Ultragenyx Pharmaceutical | Phase 1 | 28 |